Literature DB >> 8160823

Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma.

M E Carr1, S L Zekert.   

Abstract

Clot retraction, measured by serum expression, is absent in some cases of multiple myeloma. Decreased clot retraction has been attributed to platelet dysfunction. A new instrument allows simultaneous measurement of platelet-mediated force development during clot retraction and of clot elastic modulus. We report 10 patients with immunoglobulin (Ig) G myeloma in whom the abnormalities of fibrin structure were quantitatively defined and platelet-fibrin interactions were assessed. Fiber mass-to-length ratios were calculated from gel turbidity. Platelet force development and clot elastic modula were measured in platelet-rich plasma gels. Fiber mass-to-length ratios for IgG myeloma patients were smaller (means +/- SE) (0.98 +/- 0.19 x 10(13) Da/cm) than for normal controls (1.36 +/- 0.06 x 10(13) Da/cm), indicating thinner fiber formation. Elastic modula of myeloma clots (51,013 +/- 14,660 dyn/cm2) were strikingly larger than modula for normal controls (23,355 +/- 1,887 dyn/cm2), indicating that such clots are mechanically less flexible. Platelet force development 1,200 s after thrombin addition was not diminished in myeloma patients (8,315 +/- 1,155 dyn) vs. controls (6,906 +/- 606 dyn). Abnormal clot retraction in myeloma appears to be primarily due to altered clot structure rather than platelet dysfunction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160823     DOI: 10.1152/ajpheart.1994.266.3.H1195

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Feeling the Force: Measurements of Platelet Contraction and Their Diagnostic Implications.

Authors:  Evelyn Kendall Williams; Oluwamayokun Oshinowo; Abhijit Ravindran; Wilbur A Lam; David R Myers
Journal:  Semin Thromb Hemost       Date:  2018-12-19       Impact factor: 4.180

2.  Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.

Authors:  Marcus E Carr; Thomas P Loughran; John A Cardea; Wade K Smith; Jan G Kuhn; Maribeth V Dottore
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Photoacoustic Fibrinolysis: Pulsed-Wave, Mid-Infrared Laser-Clot Interaction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

4.  Validation study toward measuring the mechanical properties of blood clots using resonant acoustic spectroscopy with optical vibrometry.

Authors:  Gongting Wu; Alisa S Wolberg; Amy L Oldenburg
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2012-02-28

5.  The biophysics and mechanics of blood from a materials perspective.

Authors:  Yongzhi Qiu; David R Myers; Wilbur A Lam
Journal:  Nat Rev Mater       Date:  2019-03-28       Impact factor: 66.308

6.  Quantitative structural mechanobiology of platelet-driven blood clot contraction.

Authors:  Oleg V Kim; Rustem I Litvinov; Mark S Alber; John W Weisel
Journal:  Nat Commun       Date:  2017-11-02       Impact factor: 14.919

7.  Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.

Authors:  Hailey A Baker; Alexandra R Brown; Jonathan D Mahnken; Theresa I Shireman; Carol E Webb; Brea C Lipe
Journal:  Cancer Med       Date:  2018-12-25       Impact factor: 4.452

Review 8.  Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.

Authors:  Claire Comerford; Siobhan Glavey; Jamie M O'Sullivan; John Quinn
Journal:  Cancer Drug Resist       Date:  2022-03-07

9.  Association between left ventricular function and paraprotein type in patients with multiple myeloma.

Authors:  Jeong-Eun Yi; Sung-Eun Lee; Hae-Ok Jung; Chang-Ki Min; Ho-Joong Youn
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.